# Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy

> **NCT03042221** · — · RECRUITING · sponsor: **University of Colorado, Denver** · enrollment: 100 (estimated)

## Conditions studied

- Non-Small Cell Carcinoma of Lung, TNM Stage 4
- Non-Small Cell Lung Cancer
- EGFR Gene Mutation
- ALK Gene Mutation
- ROSE Cluster 1
- BRAF V600E

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03042221
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2016-05-10
- **Primary completion:** 2026-11-01
- **Final completion:** 2027-09-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03042221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03042221, "Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03042221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*